StockData
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp (ABUS) stock

ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$4.03+0.15 (+3.87%)

Close on Nov 12, 2026Market cap $797.33MP/E 3.6Yield –

Arbutus Biopharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Arbutus Biopharma's price to sales ratio was 4.2× on Nov 11, 2026, against 58.0× a year earlier. Over the last 5 years it ranged from 4.2× to 109.3×, with a median of 26.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.2×−59.0
2025Dec 31, 202563.2×−28.7
2024Dec 31, 202491.9×+73.0
2023Dec 29, 202318.9×+9.0
2022Dec 30, 20229.9×−32.3
2021Dec 31, 202142.2×−6.7
2020Dec 31, 202048.9×+22.8
2019Dec 31, 201926.0×−5.2
2018Dec 31, 201831.2×−3.6
2017Dec 29, 201734.9×+25.5
2016Dec 30, 20169.3×−5.3
2015Dec 31, 201514.7×−15.0
2014Dec 31, 201429.7×+21.6
2013Dec 31, 20138.1×+4.5
2012Dec 31, 20123.6×–

More Arbutus Biopharma figures

See a number that looks wrong?